Introduction
Chronic myeloid leukemia (CML) is a malignant clonal disorder of hematopoietic stem cells that results in increased and deregulated growth of myeloid cells (Sawyers, 1999) . Approximately 95% of CML cases arise from the formation of the Philadelphia (Ph) chromosome, a product of a chromosomal translocation that brings together the c-abl gene on chromosome 9 and the bcr gene on chromosome 22. This translocation results in the creation of the BCR-ABL fusion protein, which is a constitutively active tyrosine kinase (Sawyers, 1999) . As a consequence of increased tyrosine kinase activity, BCR-ABL phosphorylates substrates, including Grb2, Crkl and Shc, and activates signaling cascades, such as the Ras pathway, PI3K/Akt and Stat5, affecting the growth and differentiation of myeloid cells (Diaz-Blanco et al., 2007) .
Nuclear factor-kappa B (NF-kB) is a transcription factor, comprised of five family members: p65 (RelA), RelB, c-Rel, p50/p105 (NF-kB1) and p52/p100 (NFkB2). These proteins share a conserved Rel homology domain, which controls DNA binding, dimerization and interaction with inhibitory IkB proteins (Courtois and Gilmore, 2006; Basseres and Baldwin, 2006) . NF-kB activation typically occurs through one of two distinct pathways. In the classical pathway, the p50-p65(RelA) heterodimer is activated by the IkB kinase (IKK) complex, which contains two catalytic subunits, IKKa and IKKb, and a regulatory subunit, IKKg. IKK phosphorylates IkBa, an inhibitory protein that normally sequesters p50-p65 in the cytoplasm, causing it to become ubiquitinated and subsequently degraded, allowing NF-kB to accumulate in the nucleus. In the alternative pathway, IKKa homodimers are activated and subsequently phosphorylate p100. This results in the proteolytic processing of p100 to p52 and allows p52-RelB dimers to translocate to the nucleus (Hayden and Ghosh, 2004) . Once in the nucleus, NF-kB is known to regulate the expression of a variety of genes, including those encoding cytokines and cytokine receptors, inflammatory mediators and anti-apoptotic proteins (Basseres and Baldwin, 2006) . NF-kB is activated in many solid tumors (Basseres and Baldwin, 2006) and hematological malignancies, including CML (Braun et al., 2006) , in which it provides proliferative and cell survival mechanisms. NF-kB is activated by BCR-ABL and is required for cellular transformation and tumor formation induced by this oncoprotein (Hamdane et al., 1997; Reuther et al., 1998) . Inhibition of IKK in BCR-ABL-expressing cells induces death (Cilloni et al., 2006; Duncan et al., 2008) . Interestingly, Imatinib-and/or Dasatinib-resistant cells were shown to be susceptible to IKKb inhibition (Duncan et al., 2008) , suggesting a novel therapeutic option for CML. However, the mechanism whereby IKKb inhibition induces death of BCR-ABL-expressing cells has not been determined.
c-Jun N-terminal kinase (JNK), also known as stress-activated protein kinase, is a member of the mitogen-activated protein kinase family and is involved in the regulation of c-jun, a component of the AP-1 family of transcription factors (Leppa and Bohmann, 1999) . JNK is predominately activated by cellular stress mechanisms, including increased levels of reactive oxygen species (ROS), but can also be activated by other stimuli including cytokines and oncogenic transformation. JNK is activated by MAP kinase kinases through the phosphorylation of threonine 183 and tyrosine 185. JNK then phosphorylates c-Jun at serines 63 and 73 causing an increase in c-Jun transcriptional activity (Gupta et al., 1996) . c-Jun activity is implicated in cell transformation, proliferation and death downstream of JNK (Leppa and Bohmann, 1999; Vogt, 2001) . Interestingly, both c-jun and JNK are required for transformation of hematopoietic cells by BCR-ABL (Raitano et al., 1995) as well as their survival after transformation (Hess et al., 2002) . However, under stimuli that induce cell stress, JNK activation can lead to death (Shen and Liu, 2006; Dhanasekaran and Reddy, 2008) . JNK becomes activated by stimuli in a constitutive manner through increased intracellular ROS, and activates apoptotic and necrotic death pathways (Tang et al., 2002; Pham et al., 2004; Ventura et al., 2004; Kamata et al., 2005) .
It has been demonstrated that oncogenic transformation results in increased levels of intracellular ROS, which are used as secondary signaling molecules to increase proliferation and to promote the oncogenic potential of transformed cells (Benhar et al., 2002; Pelicano et al., 2004) . For example, oncogenic Ras leads to increased levels of ROS, which are important in oncogenic transformation and proliferation (Irani et al., 1997) . Previous reports have shown that hematopoietic cell lines transformed with BCR-ABL have increased levels of intracellular ROS (Sattler et al., 2000; Kim et al., 2005; Naughton et al., 2009) . ROS promotes PI3K-induced signaling downstream of BCR-ABL by inhibiting phosphatases, which normally limit signal transduction cascades (Naughton et al., 2009) , thereby increasing tumorigenicity.
In this study, we have explored the potential involvement of NF-kB in moderating intracellular ROS levels downstream of BCR-ABL. The results indicate that NF-kB activity functions to suppress BCR-ABL-induced ROS levels. In addition, inhibition of IKK or NF-kB leads to enhanced ROS levels and elevated JNK activity to promote cell death. The experiments reveal a key prooncogenic mechanism and demonstrate a mechanism whereby inhibition of NF-kB activity promotes cytotoxicity of certain cancer cells.
Results

Inhibition of IKKb results in apoptosis of BCR-ABL-expressing cells
Recently, we and others have shown that IKKb activity is required for survival of BCR-ABL-expressing myeloid cells, including cells with mutations resistant to the commonly used BCR-ABL inhibitors Imatinib and Dasatinib (Duncan et al., 2008; Cilloni et al., 2006) . That data showed the importance of IKKb in BCR-ABL-induced oncogenesis. However, a mechanism mediating IKK inhibitor-induced cell death and involvement of NF-kB in cell survival was not shown. As analyzed before, cell viability was measured to determine the effect of IKKb inhibition using Compound A (a well-validated IKKb inhibitor, Ziegelbauer et al., 2005) in parental 32D cells and in 32D cells stably expressing BCR-ABL p185 (32D/p185). Compound A treatment resulted in decreased cell viability similar to treatment with Imatinib, whereas Compound C, an inactive analog of Compound A, did not affect the viability of 32D/p185 cells ( Figure 1a and see Duncan et al., 2008) . The decrease in cell viability with Compound A treatment corresponds with cleavage of caspase 3, a marker of apoptosis (Figure 1b) . Similar results were seen in parental BaF3 pro-B cells and BaF3 cells-expressing BCR-ABL (Supplementary Figure S1 ). Co-incubation with ZVAD-FMK, an inhibitor of caspase activation, potently blocks Compound A-induced cell death. These results show that IKKb activity is required to block apoptosis in cells expressing BCR-ABL ( Figure 1b and Duncan et al., 2008) .
NF-kB activity is required for the survival of BCR-ABL-expressing cells Although IKKb is known to activate NF-kB through the phosphorylation-mediated ubiquitination and degradation of IkBa, it also has other targets (Hu et al., 2004; Lee et al., 2007) . Therefore, to determine whether NF-kB is necessary for the survival of BCR-ABL-expressing cells downstream of IKKb, and to rule out off-target effects of Compound A, NF-kB activity was blocked by expressing IkBa superrepressor (IkBa-SR), a form of IkBa containing serine to alanine mutations at residues 32 and 36 that prevent its phosphorylation and degradation, thereby sequestering NF-kB in the cytoplasm of the cell. Expression of IkBa-SR led to apoptosis in BCR-ABL-expressing 32D cells over time as measured by Annexin V/propidium iodide staining ( Figure 2a ) and expression of cleaved caspase 3 (Figure 2b ), whereas the viability of cells transduced with empty vector was not affected. Taken together, these results show a requirement for NF-kB activity downstream of IKKb in hematopoietic cells expressing BCR-ABL to prevent apoptosis.
IKKb inhibition in BCR-ABL-expressing cells results in the accumulation of intracellular reactive oxygen species
Although the inhibition of both IKKb and NF-kB in BCR-ABL-expressing cells results in apoptosis, the mechanism that precedes cell death remains unclear. Cells that have undergone oncogenic transformation, including those overexpressing Ras, c-myc and BCR-ABL, have increased levels of intracellular ROS (Irani et al., 1997; Sattler et al., 2000; Vafa et al., 2002) . Transformed cells utilize increased ROS as secondary signaling molecules to enhance proliferation and tumor development. However, because transformed cells harbor higher levels of ROS, a further increase in free radicals can result in apoptosis or necrosis (Pelicano et al., 2004) . As BCR-ABL expression is known to enhance reactive oxygen species production in hematopoietic cells ( Naughton et al., 2009) and NF-kB can regulate antioxidant gene expression (Tang et al., 2002; Pham et al., 2004; Kamata et al., 2005) , we asked whether IKKb inhibition with Compound A results in altered ROS levels leading to cell death. Relative ROS levels were measured in 32D/p185 cells treated with Imatinib or Compound A over time. Treatment with the BCR-ABL inhibitor Imatinib decreased intracellular ROS levels ( Figure 3a ) as previously reported (Sattler et al., 2000) , whereas IKKb inhibition using Compound A caused an increase in intracellular ROS as measured by DCFDA staining. Cells treated for 12 h (data not shown) or 16 h showed an accumulation of ROS (Figure 3 ), whereas cells treated for 1 h did not (data not shown), suggesting that an indirect mechanism leads to the accumulation of ROS in these cells. The accumulation of ROS upon treatment with Compound A is reversed through the addition of antioxidants nacetyl-cysteine (NAC) or butylated hydroxyanisole (BHA) (Figure 3b ). These data indicate that IKKb inhibition leads to significantly enhanced levels of ROS, over those induced by BCR-ABL.
NF-kB inhibits the activation of JNK downstream of BCR-ABL to promote cell survival At high levels, ROS have been shown to activate AP-1, resulting in cell death (Shen and Liu, 2006) . Interestingly, NF-kB is important for the regulation of JNK, an upstream effector of AP-1, to block death under cell stress conditions (Tang et al., 2002; Pham et al., 2004; Kamata et al., 2005) . Given the correlation between increased intracellular ROS and apoptosis in BCR-ABL-expressing cells after Compound A treatment, we asked whether NF-kB activation is important for the regulation of intracellular ROS and inhibition of JNK downstream of BCR-ABL. A time course in which 32D/ p185 cells were treated with Compound A shows that both the phosphorylation of JNK, its downstream target c-jun, and caspase-3 cleavage occur 6 h after treatment (Figure 4a ). 32D/p185 cells were transduced with empty vector or IkBa-SR to examine the effect of NF-kB inhibition on JNK activation and apoptosis downstream of BCR-ABL. Cells collected at 36 h posttransduction showed increased phosphorylation of JNK, c-jun and the cleavage of caspase 3 (Figure 4b ). Parental 32D cells expressing IkBa-SR were not affected to the same extent as 32D/p185 cells, although some apoptosis is apparent (Figure 4c ). This low level of cell death can be attributed to moderate activation of NFkB in these cells because of their dependence on IL-3 for survival (Reuther et al., 1998) . Although IL-3 is also known to activate JNK (Yu et al., 2004) , expression of IkBa-SR did not affect JNK phosphorylation in these cells. Together, these data show that NF-kB actively regulates the level of intracellular ROS and also inhibits the activation of JNK downstream of BCR-ABL to prevent cells from undergoing apoptosis.
IKKb inhibition leads to downregulation of antioxidant gene transcription
Our results show that NF-kB activity is important for the regulation of intracellular ROS and JNK activity downstream of BCR-ABL to prevent cells from undergoing apoptosis. NF-kB is known to regulate the expression of genes encoding proteins with antioxidant properties (Pham et al., 2004; Kamata et al., 2005) . Owing to the increase in intracellular ROS upon inhibition of IKKb, we asked if NF-kB transcriptionally regulates genes known to clear excess ROS from the cell. BCR-ABL-expressing cells were treated with vehicle or Compound A and quantitative real-time PCR was used to screen NF-kB target genes known to have antioxidant properties. 32D/p185 cells treated with Compound A for 12 h showed decreased levels of both Sod2 and Fth1 mRNAs (Figure 5a ), corresponding with the phosphorylation of JNK and apoptosis (Figure 4a ). This result indicates that blocking IKKb activity leads to decreased production of two known ROS scavengers, possibly resulting in accumulation of intracellular ROS and apoptosis. To rule out potential off-target effects of Compound A, IkBa-SR was overexpressed to block NF-kB activity in 32D/p185 cells. Similar to the results obtained using Compound A treatment, cells expressing IkBa-SR (Figure 5c ) also showed decreased mRNA levels of Sod2 and Fth1 (Figure 5b) , correlating with apoptosis. Overexpression of Sod2 and Fth1 did not rescue the cell death response induced by IKKb inhibition (data not shown), suggesting that multiple mechanisms controlled by IKK and NF-kB contribute to the regulation of ROS levels in oncogenically transformed cells.
JNK inhibition rescues BCR-ABL þ cells from apoptosis after Compound A treatment
Our results show that NF-kB activity regulates intracellular ROS levels and JNK activation in BCR-ABLexpressing cells. To determine the importance of JNK activity in the death of BCR-ABL-expressing cells after inhibition of NF-kB, we blocked JNK using a specific inhibitor, SP600125, and treated 32D/p185 cells with Compound A. Cells that were treated with SP600125 and Compound A showed decreased apoptosis as indicated by caspase 3 cleavage ( Figure 6a ) and fluorescenceactivated cell sorting analysis (Figure 6b ). However, cells treated with high concentrations of SP600125 (X25 mM) underwent apoptosis without IKKb inhibition, indicating that BCR-ABL-expressing cells also require low levels of JNK activity for survival as previously shown (Raitano et al., 1995; Hess et al., 2002) . Similar results were obtained from 32D/p185 cells that were treated with SP600125 upon expression of IkBa-SR (Figure 6c ). These data show that increased JNK activity is required for cell death in BCR-ABL-expressing cells when NF-kB is inhibited. These data further suggest an important role for JNK regulation and evasion of apoptosis through NF-kB downstream of BCR-ABL.
Inhibition of ROS prevents death due to IKKb inhibition in BCR-ABL þ cells
The increase in intracellular ROS in transformed cells enhances proliferation and tumorigenicity. However, these cells are also sensitive to further increases in intracellular ROS, which may lead to apoptosis (Pelicano et al., 2004) . Our data show that inhibition of NF-kB leads to a further increase in intracellular ROS, activation of JNK and apoptosis downstream of BCR-ABL. To better understand the role of NF-kB in the regulation of intracellular ROS in cells expressing BCR-ABL, we inhibited ROS and measured cell death after Compound A treatment. Interestingly, 32D/p185 cells incubated with NAC or BHA in conjunction with Compound A treatment showed a pronounced decrease in phosphorylated JNK and were resistant to apoptosis (Figures 7a  and b) . Similar results were obtained in Ba/F3 cells expressing BCR-ABL (Supplementary Figure S2) . Cells were also co-incubated with bovine catalase, an antioxidant enzyme, and Compound A, resulting in decreased JNK phosphorylation and apoptosis 
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( Figure 7c ). Lastly, 32D/p185 cells were incubated with NAC upon expression of IkBa-SR. JNK activation and apoptosis induced by the overexpression of IkBa-SR were also inhibited by NAC treatment (Figure 7d ). These results show that NF-kB activity is required to regulate increased intracellular ROS following transformation with BCR-ABL. Upon inhibition of NF-kB, the accumulation of ROS in the cell leads to the activation of JNK and apoptosis (Figure 7e ).
Discussion
Increased ROS has been documented in several cell types after oncogenic transformation and in various cancers (Benhar et al., 2002; Pelicano et al., 2004) . It was first discovered that human tumor cells produce increased amounts of hydrogen peroxide (Szatrowski and Nathan, 1991) , leading to the hypothesis that cancer cells are subject to persistent oxidative stress, possibly explaining characteristics of cancer including genomic instability and increased proliferation (Toyokuni et al., 1995 , Trachootham et al., 2009 . Indeed, several reports have shown an increase in reactive oxygen species in primary human tumors, including brain (Iida et al., 2001) , colorectal carcinoma (Toyokuni et al., 1995) , and ovarian cancer (Senthil et al., 2004) . In addition, reports showed that oncogenic transformation by Ras, c-myc and BCR-ABL lead to increased ROS, which is important for increased proliferation and tumorigenic potential (Irani et al., 1997; Felsher and Bishop, 1999; Vafa et al., 2002; Sattler et al., 2000; Kim et al., 2005; Naughton et al., 2009 ). Relative to oncogenic Ras expression, increased ROS levels were shown to be required for cellular transformation (Irani et al., 1997) . In this regard, ROS generated from the Qo site of mitochondrial complex III is required for anchorage-independent growth of Ras-transformed cells (Weinberg et al., 2010) . Overexpression of Nox1, a superoxide generator, in NIH3T3 cells results in elevated production of ROS and a transformed phenotype with increased proliferation (Suh et al., 1999) . Interestingly, Nox1 knockdown blocks Ras-transformed phenotypes including anchorage independent growth in vitro and in vivo (Mitsushita et al., 2004) . Relative to our study, ROS levels are increased downstream of BCR-ABL which leads to increased PI3K/Akt-dependent signaling through inhibition of the phosphatase PP1a (Naughton et al., 2009) . Cells transformed with BCR-ABL have high levels of ROS (Sattler et al., 2000; Kim et al., 2005; Naughton et al., 2009 ) (and see Figure 3a) , thus enhancing the sensitivity of these cells to a further increase in ROS. Treatment with agents that cause an increase in ROS in BCR-ABL-expressing cells leads to death (Zhou et al., 2003; Chandra et al., 2006; Trachootham et al., 2006 , Mao et al., 2008 Zhang et al., 2008) . One such agent, phenethyl isothiocyanate results in increased ROS and subsequent apoptosis in cells expressing both wild-type (Trachootham et al., 2006) and Imatiniband Dasatinib-resistant (Zhang et al., 2008) forms of BCR-ABL. However, the mechanism by which these compounds cause increased ROS and cell death is largely unknown.
Data described above indicate that the maintenance of moderate levels of ROS are necessary for increased proliferative capacity and tumorigenic potential while avoiding death in response to excessive accumulation of free radicals (Benhar et al., 2002; Schimmel and Bauer, 2002; Pelicano et al., 2004) . Owing to excessive strain on ROS clearing mechanisms that maintain a moderate balance of ROS, a further increase in ROS in transformed cells may result in cancer cell death (Benhar et al., 2002; Pelicano et al., 2004) , offering a novel approach to target cancer cells.
Potential therapeutic targets that may increase ROS, specifically in cancer cells, include transcription factors that control the expression of both antiapoptotic and antioxidant genes. One such transcription factor, NF-kB, has been shown to regulate the transcription of genes with antioxidant properties, such as ferritin heavy chain (Pham et al., 2004) and superoxide dismutase (Kamata et al., 2005) . NF-kB also inhibits JNK activation downstream of ROS through transcription of genes such as Gadd45 (De Smaele et al., 2001) and XIAP (Tang et al., 2001) and through the inhibition of mitogen-activated protein kinase (Kamata et al., 2005) and tyrosine phosphatases (Sattler et al., 2000) .
Our results show an important role for NF-kB activity in the maintenance of intracellular ROS and the inhibition of JNK activity downstream of BCR-ABL to prevent cell death after oncogenic transformation. Inhibition of IKKb using a chemical inhibitor, Compound A, results in apoptosis (Figure 1) , along with the accumulation of intracellular ROS (Figure 3 ) and the activation of JNK in BCR-ABL-expressing cells (Figure 4) . Similarly, expression of IkBa-SR, which blocks NF-kB activity, induces JNK phosphorylation and apoptosis (Figure 4b ). These data correlate with previous reports in which NF-kB has an important role in JNK inhibition when ROS levels increase (Sakon et al., 2003; Pham et al., 2004; Kamata et al., 2005) .
Treatment with Compound A or expression of IkBa-SR also results in decreased expression of two NF-kB target genes with antioxidant properties, Fth1 and Sod2 ( Figure 5 ). These genes have been documented in response to tumor necrosis factor-a stimulation in which tumor necrosis factor-a-induced ROS was scavenged, protecting cells from tumor necrosis factor-a-induced death in the absence of NF-kB (Pham et al., 2004; Kamata et al., 2005) . Although inhibition of NF-kB results in decreased antioxidant gene expression (Fth1 and Sod2), our preliminary data indicates that overexpression of either FTH1 or SOD2 in BCR-ABLexpressing cells is not sufficient to inhibit apoptosis in the absence of NF-kB activity. This is not surprising, as many cellular processes control the levels of ROS, indicating that other NF-kB-dependent genes and buffering systems are likely involved in this process.
Our data also show that JNK activity is involved in the initiation of apoptosis in the absence of NF-kB. Blocking JNK activity with a chemical inhibitor, SP600125, results in a decrease in death upon Compound A treatment in BCR-ABL-expressing cells. (Figure 6 ). However, cells expressing BCR-ABL appear to require JNK activity, as the inhibitor alone results in induction of apoptosis in 32D/p185 cells. Importantly, JNK activation by ROS is required for the initiation of apoptosis in the absence of NF-kB activity (Figure 7) . However, inhibition of ROS with antioxidants offers more complete protection from Compound A-induced apoptosis than inhibition of JNK with SP600125. This could simply be because of the efficiency of inhibition by these compounds, or the differences in survival could indicate a more involved role for increased ROS in apoptosis after inhibition of NF-kB. It is probable that ROS activate JNK as well as other proteins in the cell to initiate apoptosis in response to unfavorable conditions, and that inhibiting JNK only partially blocks the effect of increased ROS on cell survival.
These data show that NF-kB is required to maintain moderate levels of ROS and inhibit JNK activation downstream of BCR-ABL-induced ROS to inhibit the induction of apoptosis in a model of CML. As increased ROS is common among transformed cells, it is likely that NF-kB has an essential role in the regulation of ROS to prevent death, illustrating the potential use for IKKb inhibitors as a therapeutic in CML and possibly other cancers.
Materials and methods
Cell lines 32D and Ba/F3 hematopoietic murine cells were maintain in RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and 10% Wehiconditioned media as a source of IL-3. 32D and Ba/F3 cells stably expressing p185 or p210 BCR-ABL, respectively, were maintained in RPMI 1640 supplemented with 10% fetal bovine serum. 293Ts were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Chemicals 2 0 ,7 0 -Dichlorodihydrofluorescein diacetate (DCFDA; Calbiochem, Gibbstown, NJ, USA) was dissolved in dimethyl sulfoxide. Catalase and n-acetyl-cysteine (Sigma, St. Louis, MO, USA) were dissolved in culture media. The pH of NAC was then adjusted to 7.2 and the stock was subsequently passed through a 0.2-mm filter. Butylated hydroxyanisole (Sigma) was dissolved in ethanol. Compound A, SP600125 (Sigma) and Z-VAD-FMK (Sigma) were dissolved in dimethyl sulfoxide. All stocks were diluted to working dilutions in culture media.
Detection of ROS Cells were collected, washed twice with phosphate-buffered saline and then incubated with DCFDA at a final concentration of 10 mM for 15 min at 37 1C in the dark. Cells were then washed once with phosphate-buffered saline and analyzed immediately by flow cytometry.
Cell death staining
Cells were collected and washed twice with cold phosphatebuffered saline. Cells (5 Â 10 5 ) were resuspended in 100 ml Annexin-binding buffer (BD Pharmingen, San Diego, CA, USA) and stained with Annexin V (BD Pharmingen; 1:20) and Propidium Iodide (BD Pharmingen; 1:20) at room temperature in the dark for 15 min. A total volume of 400 ml binding buffer was subsequently added and the cells were analyzed immediately by flow cytometry.
Antibodies
Phospho-JNK (T183/Y185), JNK, Phospho-c-jun (S73), c-jun, and cleaved caspase 3 (Asp175), caspase 3 and IkBa were obtained from Cell Signaling Technologies (Danvers, MA, USA). b-Tubulin was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). b-actin was obtained from Calbiochem.
Western blotting Cells were collected, washed twice with cold phosphatebuffered saline and resuspended in lysis buffer (50 mM TrisHCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 1 mM EGTA, 1 mM Na 3 VO 4 ) supplemented with protease and phosphatase inhibitors (Roche, Indianapolis, IN, USA). Cells were incubated on ice for 15 min and the lysates were clarified by centrifugation. Equal amounts of lysates (30-50 mg) were subjected to SDS-PAGE, transferred onto a nitrocellulose membrane, blocked for 1 h at room temperature in Tris-buffered saline with 0.05% Tween-20 and 5% non-fat milk and incubated with the indicated antibodies overnight. Blots were incubated with the appropriate secondary antibody for 45 min at room temperature and developed using ECL detection reagent (GE, Buckinghamshire, UK).
Quantitative Real-time PCR Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), digested with DNase I (Promega, Madison, WI, USA), and used for reverse transcription (SuperScript II kit, Invitrogen). All Taqman primers were obtained from Applied Biosystems (Foster City, CA, USA). Expression levels of GusB were used to normalize the amount of the investigated transcripts.
Viral production and transduction
Virus was produced by transient transfection of 293T cells with pCL-10A1 (Imgenex, San Diego, CA, USA) and a retroviral vector using Fugene at a 1:1 ratio. Viral supernatant was collected 24 and 48 h post-transfection and concentrated using centrifugal filter units (Amicon Ultra, Millipore, Billerica, MA, USA). Target cells were resuspended at 0.5 Â 10 6 cells/ml in RPMI with viral supernatant in six-well plates and spun at 2500 r.p.m. for 1 h at room temperature. Cells were incubated with viral supernatant for an additional 3 h at 37 1C and then plated in RPMI for an additional 24-48 h before collecting for experiments.
